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Cyclooxygenase-2 (COX-2) is an isoform of prostaglandin H synthase induced by hypoxia and has been implicated in the growth and progression
of a variety of human cancers. In the present study, we investigated the role of phospholipase D (PLD) isozymes in cobalt chloride (CoCl2)-induced
hypoxia-driven COX-2 expression in U87MGhuman astroglioma cells. CoCl2 stimulated PLD activity and synthesis of COX-2 protein in a dose and
time-dependent manner. Moreover, elevated expression of PLD1 and PLD2 increased hypoxia-induced COX-2 expression and prostaglandin E2
(PGE2) production. Pretreatment of cells with 1-butanol, but not 3-butanol, suppressed CoCl2-induced COX-2 expression and PGE2 formation. In
addition, evidence that PLD activity was involved in the stimulation of COX-2 expression was provided by the observations that overexpression of
wild type PLD isozymes, but not catalytically inactive PLD isozymes, stimulated CoCl2-induced COX-2 expression and PGE2 production. PLD1
enhanced COX-2 expression by CoCl2 via reactive oxygen species (ROS), p38 MAPK kinase, PKC-δ, and PKA, but not ERK, whereas PLD2
enhanced CoCl2-induced COX-2 expression via ROS and p38MAPK, but not ERK, PKC-δ, and PKA. Differential regulation of COX-2 expression
mediated through PLD isozymes was comparable with that of CoCl2-induced PLD activity in these two PLD isozymes. Taken together, our results
demonstrate for the first time that PLD1 and PLD2 isozymes enhance CoCl2-induced COX-2 expression through differential signaling pathways in
astroglioma cells.
© 2007 Elsevier B.V. All rights reserved.Keywords: Cyclooxygenase-2; Prostaglandin E2; Cobalt chloride; Hypoxia; Phospholipase D1. Introduction
Cyclooxygenase (COX), also referred to as prostaglandin
endoperoxide synthase, is a key enzyme in the conversion of
arachidonic acid to prostaglandins (PGs) and other eicosanoids.
Two isoforms of COX have been identified [1]. COX-1 is
expressed constitutively in many tissues and cell types, whereas
COX-2 is inducible by a variety of factors, including cytokines,
growth factors, and tumor promoters. COX-2 is highly ex-
pressed in a number of human cancers and cancer cell lines.⁎ Corresponding author. Tel.: +82 51 510 3682; fax: +82 51 513 9258.
E-mail address: minds@pusan.ac.kr (D.S. Min).
1 These authors contributed equally to this study.
0167-4889/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2007.06.001COX-2 seems to be involved in the processes of malignant
transformation and tumor progression by affecting cell prolif-
eration, cell cycle progression, cell adhesion, apoptosis, and
angiogenesis [2]. COX-2 overexpression has been documented
in human glioma [3,4]. When the correlation between COX-2
expression and survival was examined in one study, high COX-2
expression correlated with poor survival for all malignant
gliomas and demonstrated the strongest correlation with
glioblastoma multiforme. An interesting observation in gliomas
has been the accumulation of COX-2-expressing astrocytes
during progression of oligodendrogliomas to a higher grade [5].
In light of known tumor-promoting properties of cyclooxygen-
ase in other tumors, this observation suggests that COX-2
expression may be involved in the neoplastic progression of
glioma.
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associated with poor prognosis [6]. Most solid human tumors
have focal hypoxic areas that cause low oxygen tension. Cobalt
is an essential trace compound because it plays a critical role in
the synthesis of vitamin B12. However, excessive cobalt ex-
posure can lead to various disease such as asthma, pneumonia,
or hematological abnormalities [7]. Cobalt chloride (CoCl2) has
been widely used as hypoxia mimic in both in vitro and in vivo
studies [8]. Cobalt chloride increases the generation of
oxidative stress in cells and increase the level of ROS [9–11].
Although the increase of ROS under a state of hypoxic stress
occurred after exposure to both metals and hypoxia, it was not
clear whether this was the stimulus for a hypoxic gene
response. Cobalt chloride treatment of cells in vitro has
previously been shown to induce cellular changes which are
similar to these seen after hypoxia [12,13]. It has been
demonstrated that COX-2 expression and activity are induced
by hypoxia in prostate cancer cells and human umbilical vein
endothelial cells [14,15].
Several lines of evidence have suggested a functional role for
PLD in COX-2 regulation during cell activation [16–19]. PLD
catalyzes the hydrolysis of phosphatidylcholine (PC) to generate
a lipid mediator, phosphatidic acid (PA) and has emerged as a
critical regulator of cell proliferation and survival signaling
[16,20]. PA is thought to function as a second messenger in a
wide range of physiological processes including mitogenesis,
differentiation, and ischemia [21,22]. Although two distinct
mammalian PLD isoforms, PLD1 and PLD2, have been cloned
to date [22], their physiological roles are still poorly understood.
Activation of PLD occurs through interactions of the ARF and
Rho families as well as with protein kinase C (PKC). Recently, it
has been demonstrated that PLD activity is increased by hypoxia
of PC12 cells and by transient forebrain ischemia in rat hippo-
campus [23,24]. However, the role of PLD isozymes in hypoxia-
induced COX-2 expression has not been studied in any
biological system. Therefore, we investigated the role of PLD
in the regulation of COX-2 expression of in astroglioma during
CoCl2-induced hypoxia. To the best our knowledge, this is the
first study to link PLD isozymes to CoCl2-induced COX-2
expression in any cell system.2. Experimental procedures
2.1. Materials
Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS)
and LipofectAMINE plus were purchased from Invitrogen. Rabbit polyclonal
COX-2 antibody was from Santa Cruz Biotechnology. Antibodies to phospho-
ERK, ERK, phospho-p38, p38, pan-phospho PKC, and phospho PKAwere from
Cell Signaling. A polyclonal antibody that recognizes both PLD1 and PLD2 was
generated as previously described [25]. Phosphatidylbutanol (PtdBut) standard
was from Avanti Polar Lipid. Anti-β-tubulin antibody were from Sigma (St.
Louis, MO), and NAC, PD98059, PD169316, rottelerin and H89 were from
Biomol (Plymouth Meeting, PA). [9], [10-3H] myristate was purchased from
PerkinElmer Life Sciences. Silica gel 60 A thin layer chromatography plates
were from Whatman. Horseradish peroxidase-conjugated anti-mouse IgG and
anti-rabbit IgG were from Kirkegaard and Perry Lab (Gaithersburg, MD).
Enhanced chemiluminescence (ECL) reagents and the PGE2 enzyme immu-
noassay kit were from Amersham Biosciences (Piscataway, NJ).2.2. Methods
2.2.1. Cell culture and transfection
U87 MG human astroglioma was obtained from the American Type Culture
Collection (Rockville, MD). The cells were maintained in DMEM (Life
Technologies, Inc) supplemented with 10% (v/v) heat-inactivated fetal bovine
serum under 5% CO2 For hypoxia induction, incubator conditions were either
normoxic (21% O2, 5% CO2) or hypoxic (0.5% O2, 5% CO2, balance N2) in a
humidified incubator at 37 °C. U87 cells were transiently transfected for 40 h
with expression plasmid encoding empty vector, using LipofectAMINE Plus
(Invitrogen) according to manufacturer's instructions. U87 cells stably
overexpressing wild type and catalytically inactive mutant of PLD isozyme
(K898R for PLD1, K758R for PLD2) were obtained by transfection, using
LipofectAMINE. Transfected cells were selected with G418 (700 μg/ml) for 21
days at 37 °C. At that time antibiotics-resistant colonies were pooled and
expanded for further analysis under selective conditions.
2.2.2. In vivo PLD activity
In vivo PLD activity was determined as described previously [26]. PLD
activity was assessed by measuring the formation of [3H] phosphatidylbutanol
(PtdBut), the product of PLD-mediated transphosphatidylation, in the presence
of 1-butanol. Cells in 6-well plates were serum-starved in the presence of 2 μCi/
ml [3H] myristic acid. After overnight starvation, the cells were washed three
times with 5 ml of phosphate-buffered saline (PBS) and pre-equilibrated in
serum-free DMEM for 1 h. For the final 10 min of preincubation, 0.3% 1-butanol
was included. At the end of the preincubation, cells were treated with agonists for
the indicated times. The extraction and characterization of lipids by thin-layer
chromatography were performed as previously described [26]. Radioactivity
incorporated into total phospholipids was measured, and the results were
presented as percentage of total lipid cpm incorporated into phosphatidylbutanol
to normalize the results.
2.2.3. Western blot
Cells were washed twice with ice-cold phosphate-buffered saline and then
lysed in the extraction buffer (20 mM HEPES, pH 7.2, 1% Triton X-100, 1%
sodium deoxycholate, 0.2% SDS, 200 mM NaCl, 1 mM Na3VO4, 1 mM NaF,
10% glycerol, 10 μg/ml leupeptin, 10 μg/ml aprotinin, 1 mM phenymethylsul-
fonyl fluoride). The resulting cell lysates was spun at 15,000×g in a Eppendorf
microcentrifuge for 10 min at 4 °C to pellet the unbroken cells. Protein
concentrations were determined using Bradford method with bovine serum
albumin as a standard. Protein samples were analyzed by SDS-polyacrylamide
gel electrophoresis on 8% gels and were transferred to a nitrocellulose
membrane. The blots were then blocked with 5% non-fat milk in Tris-buffered
saline-Tween 20 (25 mM Tris–HCl, 150 mM NaCl, and 0.05% Tween 20) and
incubated with appropriate primary antibodies followed by incubation with
horseradish peroxidase-conjugated secondary antibody. Immunoreactive bands
were detected using enhanced chemiluminescence. resuspended in sample
buffer.
2.2.4. PGE2 production assay
PGE2 levels were determined using an enzyme immunoassay kit according to
the manufacturer's instruction. Briefly, 50 μl of standard or sample was pipetted
into the wells of a 96well plate. Aliquots of mouse polyclonal PGE2 antibody and
PGE2 conjugated to alkaline phosphatase were then added to each well and the
plate was incubated at room temperature for 1 h. After incubation, the wells were
washed six times with 200 μl of PBS containing 0.05% Tween 20, and the TMB
substrate was added. Wells were read at 670 nm with an enzyme-linked
immunosorbent assay reader 30 min after adding substrate.
2.2.5. Luciferase assay
COX-2 promoter construct was generously provided by Dr. H. Inoue
(National Cardiovascular Center Research Institute, Japan). Briefly, the region
from −1432 to +59 bp of COX-2 promoter was cloned into pGL2. COX-2
promoter plasmid was transfected into human U87 astroglioma cells using
Lipofectamine Plus according to the manufacturer's instruction. After 24 h of
transfection, the cells were treated with or without CoCl2 for 12 h. Following
stimulation, cells were washed with PBS and lysed in luciferase lysis buffer. The
activities of firefly and Renilla luciferase in the cellular extracts were measured
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obtained by normalizing the firefly luciferase activity against the internal control
Renilla luciferase activity.
2.2.6. RNA isolation and reverse transcription PCR (RT-PCR)
Total RNAwas isolated from cells by the Trizol method. First-strand cDNA
was synthesized using 5 μg total RNA using MMLV-RTase (Promega,
Mannheim, Germany). The reaction was incubated at 80 °C for 5 min, 42 °C
for 90 min, and MMLV-RTase was inactivated at 95 °C for 5 min. The
synthesized cDNAwas amplified using COX-1, COX-2, COX-3, and GAPDH
primers with Eppendorf thermocycler (Eppendorf Scientific, Westbury, NY).
PCR reactions were cycled as follows: initial denaturation at 95 °C for 5 min and
then 30 cycles for COX-1, COX-2, COX-3 and GAPDH at 95 °C for 30 s, 57 °C
for 30 s, and 72 °C for 30 s. Forward primer of GAPDH was 5′-GTG GTC TCC
TCT GAC TTC AAC-3′, and the reverse primer was 5′-TCT CTT CCT CTT
GTG CTC TTG-3′ with 197 bp amplified fragments. The forward primer of
COX-1 gene was 5′-CAATGCCACCTTCATCCG A-3′, and the reverse primer
was 5′-GAGCCGCAGTTGATACTGA-3′with 430 bp amplified fragments. The
forward primer of COX-2 gene was 5′-CCTTCCTCCTGTGCCTGATG-3′, and
the reverse primer was 5′-TCTAGCCAGAGTTTCACCGTA-3′ with 203 bp
amplified fragments. The forward primer of COX-3 gene was 5′-CAT-
GAGCCGTGAGTGCG-3′, and the reverse primer was 5′-CTGCAGAGGA-
GAGAGATGAG-3′ with 102 bp amplified fragments. PCR products were
analyzed by 2% agarose gel electrophoresis with ethidium bromide staining.
2.2.7. Statistics
The results are expressed as mean±S.D. of the number of determinations
indicated. Statistical significance of differences was determined by ANOVA.
Significance was accepted when pb0.05.Fig. 1. Elevated expression of PLD isozymes upregulates CoCl2, PMA, or LPS-
induced COX-2 expression and PGE2 production in human astroglioma cells.
U87 MG human astroglioma cells overexpressing vector, PLD1 or PLD2 were
stimulated without or with 200 μMof CoCl2 (A), 20 nM of PMA (B) or 10 μg/ml
of LPS (C) for 20 h. Equal amounts of cell lysates (40 μg) were analyzed by SDS-
polyacrylamide gel electrophoresis, followed by transfer of proteins to
nitrocellulose membrane and immunoblotting with antibodies to COX-2, PLD
or β-tubulin antibody. (D) U87 MG cells were treated with or without CoCl2
(500 μM) for 6 h. and RT-PCR analysis was performed as described in
Exprimental procedures. The data shown are representative of three independent
experiments. (E) The release of PGE2 was measured from supernatants as
described in Exprimental procedures. The values shown for PGE2 production are
the mean±S.D. of the three independent experiments.3. Results
3.1. Elevated expression of PLD isozymes upregulates
CoCl2–induced COX-2 expression and PGE2 production in
human astroglioma cells
Cobalt has been widely used as a hypoxiamimic agent both in
vitro and in vivo studies. It has been reported that CoCl2 induces
COX-2 protein levels in prostate cancer cells [27]. To investigate
the effect of PLD on CoCl2-induced COX-2 expression, we
established U87 MG human astroglioma cells stably over-
expressing vector, PLD1, or PLD2. In unstimulated cells,
elevated expression of PLD1 or PLD2 led to somewhat higher
basal expression of COX-2 protein compared with that of vector
(Fig. 1A). In CoCl2-stimulated cells, overexpression of PLD1 or
2 significantly increased COX-2 expression, compared with that
of control cells (Fig. 1A), suggesting that elevated expression of
PLD1 or PLD2 enhances CoCl2-induced COX-2 expression. On
the other hand, COX-2 is expressed transiently by a wide
spectrum of growth factors and pro-inflammatory stimuli under
certain pathophysiological conditions [28–30]. Elevated expres-
sion of PLD also increased PMA or lipopolysaccharide (LPS)-
induced COX-2 expression in U87 astroglioma cells (Fig. 1B
and C), COX-2 but not COX-1 and -3, was present in U87
astroglioma cells, and CoCl2 increased the expression of COX-
2, but not COX-2 and COX-3, using RT-PCR. (Fig. 1D),
suggesting that CoCl2 is responsible for induction of COX-2.
Because COX-2 catalyzes biosynthesis of prostaglandin E2
(PGE2), we examined whether this enzyme was responsible for
CoCl2-induced PGE2 production. CoCl2, PMA, and LPS
increased PGE2 biosynthesis in the culture media of cells stimu-lated with these agents (Fig. 1E). CoCl2, PMA or LPS-induced
PGE2 increase was also enhanced by elevated expression of PLD
isozymes compared with that of vector cells (Fig. 1E). Both
PLD1 and PLD2 contribute to CoCl2-induced PGE2 production
in a similar extent in human astroglioma cells. Furthermore,
CoCl2-induced COX-2 protein expression was enhanced in a
dose- and time-dependent manner in cells overexpressing of
PLD isozymes compared with that of vector cells (Fig. 2A and
B). Overexpression of PLD isozymes also increased CoCl2-
induced PGE2 production in a dose-dependent manner com-
Fig. 3. Hypoxia-induced COX-2 expression is increased by overexpression of
PLD isozymes. U87 MG human astroglioma cells overexpressing PLD1, PLD2,
or vector were incubated for 12 h in the normoxia or in the hypoxia condition
(0.5% O2). (A) The cell lysates were immunodetected with anti-COX-2 or anti-
β-tubulin antibody. The data shown are representative of three independent
experiments. (B) The release of PGE2 was measured from supernatants from
normoxic and hypoxic culture. The values shown for PGE2 production are the
mean±S.D. of the three independent experiments.
Fig. 2. Overexpression of PLD1 and PLD2 enhances CoCl2-induced COX-2
expression and PGE2 formation in a dose and time-dependent manner. (A) U87
MG human astroglioma cells overexpressing PLD1, PLD2, or vector were
treated with or without various concentration of CoCl2 for 20 h or 500 μM
CoCl2 for the times indicated. The cell lysates were prepared and analyzed for
COX-2 expression by Western blot analysis. These blots are representative of
results obtained from three experiments. (B) Cells were stimulated with the
indicated concentrations of CoCl2 for 20 h, and then the release of PGE2 was
measured from supernatants as described in Exprimental procedures. The values
shown for PGE2 production are the mean±S.D. of the three independent
experiments.
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elevated expression of PLD isozymes up-regulates CoCl2-
induced COX-2 expression and PGE2 biosynthesis in U87 MG
human astroglioma cells.
3.2. Hypoxia-induced COX-2 expression is increased by
overexpression of PLD isozymes
It has been reported that hypoxia increases COX-2 protein
levels in prostate cancer cells [31]. Therefore, we examined
whether hypoxia-induced COX-2 expression is increased by
elevated expression of PLD isozymes. The hypoxia effect was
investigated under 0.5% O2 and U87MG astroglioma cells were
incubated under hypoxic or normoxic conditions for 12 h.
Hypoxia stimulated COX-2 expression and elevated expression
of PLD1 or PLD2 led to higher expression of COX-2 protein in
normoxic condition, compared with that of vector cells (Fig.
3A). Furthermore, overexpression of PLD1 and PLD2 up-regulated hypoxia-induced COX-2 expression compared with
that of vector cells. Hypoxia-induced PGE2 production was also
increased by elevated expression of PLD isozymes and com-
parable with the result of hypoxia-induced COX-2 expression
(Fig. 3B). These results suggest that elevated expression of PLD
isozyme enhances COX-2 expression and PGE2 formation in-
duced by hypoxic culture.
3.3. PLD activity is involved in CoCl2-induced COX-2
expression and PGE2 production
To address the possible involvement of PLD activation in
CoCl2-induced COX-2 expression and PGE2 biosynthesis, U87
human astroglioma cells prelabeled with [3H] myristate were
stimulated with 500 μM CoCl2 for various times. And PLD
activity was measured by the formation of [3H] PtdBut from
1-butanol, a product specific to PLD activity. As shown in Fig.
4A and B, CoCl2 induced PtdBut formation, in a time- or dose-
dependent manner. CoCl2-induced PLD activation was sig-
nificantly increased by elevated expression of PLD1 and PLD2.
Furthermore, PMA-induced PLD activation was also increased
by PLD overexpression (Fig. 4C). Although the experiments
showed that PLD was activated in CoCl2-treated human
astroglioma cells, they provided no direct evidence that PLD
activity was involved in the induction of COX-2 expression. We
then examined whether PLD activity affects COX-2 expression
and PGE2 production in CoCl2-stimulated cells (Fig. 5). Fig. 5A
Fig. 4. Activation of PLD by CoCl2 in astroglioma cells. U87 MG human
astroglioma cells overexpressing PLD1, PLD2, or vector were cultured in six-
well plates and labeled with 2 μCi/ml [3H] myristic acid. Following washing and
preincubation with DMEM, 0.1% BSA, 0.3% 1-butanol for 20 min, the cells
were treated with 500 μM CoCl2 for the indicated times (A), with the indicated
concentration of CoCl2 for 1 h (B), or 100 nM PMA for 1 h (C). The radio-
activity incorporated into PtdBut was measured as described in Exprimental
procedures. Data are expressed as the mean of the means±S.D. of three
independent experiments.
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overexpressing wild-type PLDs and catalytically inactive
mutant PLDs. CoCl2-induced COX-2 expression and PGE2
formation were significantly increased in cells expressing wild
type PLDs compared with that in vector-transfected control
cells, whereas there was no increase of COX-2 protein and PGE2
formation by treatment of CoCl2 in cells expressing the cataly-tically inactive mutants of PLD, suggesting that these effects are
clearly PLD activity dependent (Fig. 5B, C). A role for PLD
activity in CoCl2-induced COX-2 expression received further
support when 1-butanol was used to block PA production by
PLD, by virtue of the formation of phosphatidylbutanol through
the transphosphatidylation reaction. U87 MG cells were stimu-
lated with CoCl2 in the presence of 1% 1-butanol or 3-butanol.
As shown in Fig. 5D, 1-butanol, but 3-butanol inhibited CoCl2-
induced COX-2 expression and PGE2 biosynthesis. This activity
dependency was further confirmed by measuring the promoter
activity of COX-2 gene. A luciferase reporter plasmid contain-
ing genomic fragment corresponding to the COX-2 promoter
was transfected into cells expressing vector, wild-type PLD1 or
PLD2, or the catalytically inactive mutants of PLD1 and PLD2.
As shown in Fig. 5E, COX-2 promoter activity was increased by
treatment with CoCl2. CoCl2,-induced COX-2 promoter activity
was significantly increased by elevated expression of wild-type
PLD1 and PLD2, but not catalytically inactive mutants of PLD1
and PLD2. Taken together, these results show that CoCl2-
induced COX-2 expression and PGE2 formation are increased
by a PLD dependent pathway.
3.4. PLD1 and PLD2 differentially regulate CoCl2-induced
COX-2 expression
We tried to investigate the signaling pathway of CoCl2-
induced COX-2 expression via PLD isozymes. As shown in Fig.
6A, anti-oxidant (NAC) and p38 MAPK inhibitor (PD169316)
suppressed CoCl2-induced COX-2 expression in both PLD1 and
PLD2-overexpressed astroglioma cells, suggesting that reactive
oxygen species (ROS) and p38 MAPK are involved in CoCl2-
induced COX-2 expression via both PLD1 and PLD2 isozymes.
It is known that CoCl2 can mimic the hypoxia responses in many
respects, including production of ROS in cultured cells [32]. The
inhibitor of p42/44 MAPK, which is known to regulate COX-2
expression, did not affect the CoCl2-induced COX-2 expression
in PLD1 and PLD2-overexpressed astroglioma cells. Interest-
ingly, PKC-δ specific inhibitor, rottelerin and PKA inhibitor,
H89 significantly suppressed CoCl2-induced COX-2 expression
in PLD1-overexpressed cells, but not PLD2-overexpressed
cells. In addition, we examined transcriptional activation of
COX-2 using the luciferase reporter plasmid containing COX-2
promoter. CoCl2-induced COX-2 promoter activity in PLD1-
overexpressed cells was suppressed by pretreatment with anti-
oxidant (NAC), p38MAPK inhibitor, PLC-δ inhibitor, and PKA
inhibitor (Fig. 6B), but not MEK inhibitor, whereas CoCl2-
induced COX-2 promoter activity in PLD2-overexpressed cells
was suppressed by pretreatment with anti-oxidant and p38
MAPK inhibitor, but not PLC-δ inhibitor, PKA inhibitor, and
MEK inhibitor (Fig. 6C). These results were correlated with
those of CoCl2-induced COX-2 protein expression, suggesting
differential regulation of COX-2 by PLD isozymes. As shown in
Fig. 6D, the phosphorylation of ERK by CoCl2 increased
gradually and peaked at 20 min and decreased thereafter. CoCl2
stimulated significantly p38 MAPK, and CoCl2- induced p38
MAPK peaked at 10 min and then declined. Although CoCl2
stimulated phosphorylation of ERK and p38 MAPK in U87
Fig. 5. PLD activity is involved in CoCl2-induced COX-2 expression. (A) Upper panel: Activity of PLD in U87 MG human astroglioma cells overexpressing vector
(Vec), wild-type PLD1 (wtPL1), PLD2 (wtPLD2), and their catalytically inactive mutants, PLD1 (mtPLD1), PLD2 (mtPLD2) were measured as described in
Exprimental procedures. Expression of PLD isozymes were analyzed using antibody to PLD. (B) The cells were treated with 200 μM of CoCl2 for 12 h and cell lysates
were immunoblotted with an antibody directed against COX-2 or an anti-β-tubulin antibody. The data shown are representative of three independent experiments. (C)
The release of PGE2 was measured from supernatants as described in Exprimental procedures. The values shown for PGE2 production are the mean±S.D. of the three
independent experiments. (D) Upper panel: U87 cells were stimulated with 200 μM of CoCl2 in the presence of 1% butanol or 3-butanol for 12 h. The release of PGE2
was measured from supernatant, Lower panel: The extracted proteins were immunodetected with anti-COX-2 or anti-β tubulin antibody. (E) The cells were transfected
with 25 ng of the reporter plasmid, pGL2-COX-2. After 12 h of transfection, cells were treated without or with 200 μM of CoCl2 for 12 h, and luciferase activity was
measured. The internal control vector (pRL-null) was used to normalize for transfection efficiency. Results show means±S.D. of three independent experiments.
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CoCl2 -induced COX2 expression via activation of p38 MAPK,
but not ERK. We also found that CoCl2 activated PKC and PKAin a time-dependent manner in U87 astroglioma cells using
antibodies to pan-phospho-PKC and phospho-PKA (Fig. 6D).
Furthermore, CoCl2-induced PLD activation was also com-
Fig. 6. Differential regulation of CoCl2-induced COX-2 expression by PLD isozymes. (A) U87 cells overexpressing PLD1 or PLD2 were pretreated with NAC
(10 mM), PD98059 (10 μM), PD169316 (10 μM), Rottlerin (10 μM), and HA89 (10 μM) for 30 min followed by stimulation with CoCl2 (200 μM) for 12 h. Cell
lysates were prepared and analyzed for COX-2 by Western blot analysis, using a specific antibody. These blots are representative of results obtained from three
experiments. U87 cells overexpressing PLD1 (B) or PLD2 (C) was transfected with COX-2-Luc. After 12 h of transfection, cells were pretreated with the indicated
inhibitors for 30 min and stimulated without or with CoCl2 (200 μM) for 12 h, and luciferase activity was measured. The internal control vector (pRL-null) was used to
normalize for transfection efficiency. Results show means±S.D. of three independent experiments. (D) U87 cells were stimulated with CoCl2 (200 μM) for the
indicated times. Cell lysates were immunoblotted with the indicated antibodies. Data are representative of three experiments.
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PLD1 activation by CoCl2 was suppressed in a dose-dependent
manner by PD169316, rottlerin, and HA89, whereas CoCl2-
induced PLD2 activation was inhibited by PD169316, but not by
rottlerin, and HA89. Both PLD 1 and PLD2 were also sup-
pressed by antioxidant (NAC), but not by PD98059. These
results suggest that PLD1 and PLD2 differentially regulate
CoCl2-induced COX-2 expression in astroglioma cells.
3.5. CoCl2 also stimulates PGE2 production via PLA2 and
PLC signaling pathway, but pertussis toxin-insensitive manner
It has been known that hypoxic injury also involve the
stimulation of phospholipase A2 (PLA2) and phospholipase C
(PLC) in brain tissue [33]. PLA2 and PLC liberate arachidonic
acid, which is the substrate for COX, the enzyme that produces
PGE2 [34,35]. Therefore, we examined relative contribution of
PLA2, PLC and PLD in CoCl2-induced PGE2 production usingits specific inhibitors (Fig. 8A). The cytosolic PLA2 inhibitor
(AACOCF3) and PLC inhibitor (U73122) suppressed CoCl2-
induced PGE2 production in a similar extent, but PLD inhibitor
(1-butanol, which blocks PA formation by PLD) showed
dramatic decrease in CoCl2-induced PGE2 production compared
with those of other two phospholipases, suggesting that PLD
mainly contributes to CoCl2-induced PGE2 production and both
PLA2 and PLC are also in a similar extent involved in the
phenomena. Furthermore, we examined whether G protein is
involved in the CoCl2-induced PGE2 production. As shown in
Fig. 8B, pertussis toxin, which catalyzes ADP ribosylation of the
Gi family of the α subunits, thus uncoupling them from their
activating receptors, did not affect CoCl2-induced PGE2
production in PLD1 or PLD2-expressed astroglioma cells.
Taken together, these results suggest that in U87 human
astroglioma cells, PLD mainly contributes to CoCl2-induced
PGE2 production and PLA2 and PLC signaling pathway are also
involved, but pertussis toxin-insensitive manner.
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The major finding of this study is that PLD is a vital
component of the signal transduction pathway induced by CoCl2
or hypoxia that leads to the expression of COX-2 in human
astroglioma. Cellular responses to either CoCl2 or hypoxia share
a common mechanism for oxygen sensing, signal transduction,
and transcriptional regulation [36,37]. The present study created
an in vitro hypoxia-like state by treatment of astroglioma cells
with CoCl2 and demonstrates that astroglioma cells increase
levels of COX-2 in the presence of CoCl2, but not COX-1 and
COX-3. It has been reported that COX-2-positive cells
accumulated in human glioma tumor cells, but no COX-1
immunoreactivity was observed in the tumor cells [38]. More-
over, it has been reported that VEGF induction by CoCl2-
stimulated hypoxia is mediated by induction of COX-2
expression in a human metastatic prostate cancer cell line [27].
It was also suggested that significant expression of COX-2 of
neoplastic astrocytes may represent induction of COX-2 byFig. 7. Differential regulation of CoCl2-induced PLD activation. U87 cells overexpre
[3H] myristic acid. Following washing and preincubation with DMEM, the cells were
(C) for 30 min, and then stimulated with 500 μMCoCl2 for 1 h. The labeled cells were
stimulation with CoCl2 (500 μM) for 1 h (D). The radioactivity incorporated into PtdB
the mean of the means±S.D. of three independent experiments. ⁎pb0.05 vs. controhypoxia or hypoglucosemia, as has been observed in brain
infarcts [39]. COX-2 overexpression in astrocytic glioma is
intimately related to features of biological aggressiveness in
astrocytic gliomas, i. e. histological grade and proliferative po-
tential and closely associated with vascular surface area and the
expression of the angiogenic factor VEGF, known to drive
angiogenesis in these tumors.
Little is known about howCOX-2 protein levels are regulated
in glioma cells, the PLDs responsible for such a regulation, and
the molecular mechanisms involved. We have studied signal
transduction pathways involved in CoCl2-induced COX-2
expression in U87 MG astroglioma cells. CoCl2 stimulated
COX-2 protein expression and PGE2 production as well as PLD
activity.
Some studies have implicated a PLD-derived signaling path-
way in the generation of prostaglandins in many cell types [16–
19]. Kaneki et al. [40] showed that PMA-induced COX-2
expression in osteoblast-like UMR-106 cells was dependent
upon PLD activity.ssing PLD1 or PLD2 were cultured in six-well plates and labeled with 2 μCi/ml
pretreated with the indicated concentration of PD98059 (A), Rottlerin (B), HA89
also pretreated with NAC (20 mM) or PD98059 (10 μM) for 30 min followed by
ut was measured as described in Exprimental procedures. Data are expressed as
l.
Fig. 8. PLD mainly contribute to CoCl2-induced PGE2 production and both
PLA2 and PLC, but not pertussis toxin-sensitive G protein, are involved in
CoCl2-induced PGE2 production. (A) U87 cells were pretreated with AACOCF3
(10 μM), U73122 (10 μM), or 1-butanol (0.3%), and treated with CoCl2
(500 μM) for 24 h. (B) U87 cells expressing vector, PLD1 or PLD2 were
pretreated with pertussis toxin for 30 min and stimulated with 500 μMCoCl2 for
24 h. The release of PGE2 was measured from supernatants as described in
Exprimental procedures. The values shown for PGE2 production are the mean±
S.D. of the three independent experiments. ⁎pb0.05 vs. control.
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hypoxic incubation [23] and in reactive astrocytes the
hippocampus after transient forebrain ischemia [24]. CoCl2
has been widely used as a hypoxia mimic in both in vitro and in
vivo studies [8]. There is no direct evidence that indicates
direct regulation of COX-2 expression by PLD protein levels.
Our observation that elevated expression of wild types of PLD
isozymes, but not catalytically inactive mutants of PLD iso-
zymes, leads to increased expression of COX-2 by CoCl2,
clearly indicates a positive role for PLD isozyme in CoCl2 –
induced COX-2 expression in human U87 MG astroglioma
cells. The evidence implicating PLD activity as an important
component of these functional events relies on the use of
alcohols. Importantly, inhibition of phosphatidic acid formation
through the addition of the primary alcohol 1-butanol, but not
tertiary butanol, suppressed CoCl2 induction of COX-2
expression and PGE2 formation. Therefore, our findings
imply that PLD activity is an important factor in the sup-pression of CoCl2-induced COX-2 expression and PGE2
production.
PLA2 and PLC is known to be involved in PGE2 production.
In U87 human astroglioma cells, PLD mainly contributes to
CoCl2-induced PGE2 production, and both PLA2 and PLC are
also involved in the similar extent in the formation of PGE2 by
CoCl2. Since PLA2, PLC, and PLD are the part of signal
transduction network, it is possible that cross-talk among these
phospholipases in CoCl2-induced COX2 expression and PGE2
production. It has been reported that COX-2 expression can be
regulated through different signaling pathways and that the
particular signaling pathway involved is dependent on the type
of stimuli [28]. Recently, we have reported that PLD isozymes
mediate epigallocatechin gallate (EGCG)-induced COX-2
expression through PKC and p38 MAPK in U87 MG
astroglioma cells [17]. Park et al. [18] demonstrated that in
human amnion cells, IL-1β might activate PLD through an
upstream protein kinase C to elicit p38 and finally induce COX-2
expression. It was reported that induction of COX-2 by
interleukin-1 is mediated by both ERK and p38 kinase in
murine astrocytes [30]. In the present study, we observed that
elevated expression of PLD1 and PLD2 isozymes regulated
differentially CoCl2-induced COX-2 expression in U87 MG
astroglioma cells. Although CoCl2 stimulated phosphorylation
of ERK and p38 MAPK in U87 astroglioma cells, both PLD1
and PLD2 isozymes may mediate CoCl2 -induced COX2
expression via activation of p38 MAPK, but not ERK. CoCl2
also stimulated phosphorylation of PKC and PKA. PLD1
increased CoCl2 induction of COX-2 expression via ROS, p38
MAPK, PKC-δ, and PKA, but not ERK, whereas PLD2
increased CoCl2-induced COX-2 expression via ROS and p38
MAPK, but not ERK, PKC-δ, and PKA. It is likely that PLD1
and PD2 act interchangeably as well as in parallel to transducer
signal. Pertussis-sensitive G protein was not involved in CoCl2-
induced PGE2 upregulation via PLD1 and PLD2.
It was suggested that PLD either acts on a discrete pool of
substrate phosphatidylcholine (PC) separate from the bulk of
cellular PC, or that the enzyme exhibits a degree of substrate
specificity for selected PCmolecular species [41] Therefore, it is
possible that PLD1 and PLD2 act on different molecular species
of PC in various cellular pools located in various subcellular
fractions of human astroglioma cells.
An emerging issue in cancer research is the focus on the
mechanistic link between chronic inflammation and carcinogen-
esis, including tumor angiogenesis [42]. COX-2 is an important
inducible enzyme mediating inflammatory processes and is
highly expressed in a diversity of cancer [43].Malignant gliomas
are among the most common tumors of the central nervous
system. COX-2 protein expression in malignant gliomas is an
interesting phenomenon, particularly in light of its better-defined
role in tumorigenesis in other cancers. COX-2 expression in
malignant gliomas has been associated with a higher tumor
grade and worse prognosis. PLD has been also known to be
involved in many aspects of cell proliferation, survival, and
metastasis [44].
To the best of our knowledge, this is the first report to show
that CoCl2 might activate differentially PLD1 and PLD2 iso-
1730 B.-H. Ahn et al. / Biochimica et Biophysica Acta 1773 (2007) 1721–1731zymes and finally induce COX-2 expression. Further studies on
physiological role of PLD in the cobalt chloride-stimulated
COX-2 regulation in astroglioma cells.
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